Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: Mini review

Oncotarget

Volumn 8, Issue 70, 2017, Pages 115774-115786

  Yu, Li ^a   Li, Kefeng ^b   Zhang, Xiaoye ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Lung cancer; Next generation metabolomics; Pathogenesis; Precision medicine

Indexed keywords

ACETYLCARNITINE; ALANINE; ASPARTIC ACID; BENZOIC ACID; BENZYL ALCOHOL; BILIRUBIN; CARNITINE; CHOLINE; CITRIC ACID; CYSTEINE; GLUCOSAMINE; GLUCOSE; GLUTAMIC ACID; GLYCEROL; HYDROXYBUTYRIC ACID; HYDROXYLAMINE; INOSITOL; LACTIC ACID; LINOLEIC ACID; LYSINE; MERCAPTAMINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHORIC ACID; PHOSPHORYLCHOLINE; PUTRESCINE; SPHINGOSINE; THREONINE; TRYPTOPHAN; UNINDEXED DRUG; VALINE;

CANCER CLASSIFICATION; CANCER RESEARCH; EARLY DIAGNOSIS; FATTY ACID SYNTHESIS; GLYCOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG CANCER; LUNG LAVAGE; MASS FRAGMENTOGRAPHY; METABOLOMICS; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PERSONALIZED MEDICINE; REVIEW; UPREGULATION;

EID: 85039755566     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.22404     Document Type: Review

References (59)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-32. https://doi.org/10.3322/caac.21338
2. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15: 473-84. https://doi.org/10.1038/nrd.2016.32
3. Fiehn O, Kopka J, Dörmann P, Altmann T, Trethewey RN, Willmitzer L. Metabolite profiling for plant functional genomics. Nat Biotechnol. 2000; 18: 1157-61. https://doi. org/10.1038/81137
4. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013; 501: 355-64. https://doi.org/10.1038/nature12627
5. Callejón-Leblic B, García-Barrera T, Grávalos-Guzmán J, Pereira-Vega A, Gómez-Ariza JL. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform. J Proteomics. 2016; 145: 197-206. https://doi.org/10.1016/j. jprot.2016.05.030
6. Hao D, Sarfaraz MO, Farshidfar F, Bebb DG, Lee CY, Card CM, David M, Weljie AM. Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment. Metabolomics. 2016; 12: 58. https:// doi.org/10.1007/s11306-016-0961-5
7. Peralbo-Molina A, Calderón-Santiago M, Priego-Capote F, Jurado-Gámez B, Luque de Castro MD. Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate. J Breath Res. 2016; 10: 026002. https://doi. org/10.1088/1752-7155/10/2/026002
8. Fahrmann JF, Grapov D, DeFelice BC, Taylor S, Kim K, Kelly K, Wikoff WR, Pass H, Rom WN, Fiehn O, Miyamoto S. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomark. 2016; 16: 609-17. https://doi. org/10.3233/CBM-160602
9. Cameron SJ, Lewis KE, Beckmann M, Allison GG, Ghosal R, Lewis PD, Mur LA. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer. 2016; 94: 88-95. https://doi.org/10.1016/j.lungcan.2016.02.006
10. Puchades-Carrasco L, Jantus-Lewintre E, Pérez-Rambla C, García-García F, Lucas R, Calabuig S, Blasco A, Dopazo J, Camps C, Pineda-Lucena A. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget. 2016; 7: 12904-16. https://doi.org/10.18632/oncotarget.7354
11. Santini G, Mores N, Penas A, Capuano R, Mondino C, Trové A, Macagno F, Zini G, Cattani P, Martinelli E, Motta A, Macis G, Ciabattoni G, Montuschi P. Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease. Curr Top Med Chem. 2016; 16: 1610-30. https://doi.org/10.2174/1568026616666151223113540
12. Chen W, Lu S, Ou J, Wang G, Zu Y, Chen F, Bai C. Metabonomic characteristics and biomarker research of human lung cancer tissues by HR1H NMR spectroscopy. Cancer Biomark. 2016; 16: 653-64. https://doi.org/10.3233/ CBM-160607
13. Li T, He J, Mao X, Bi Y, Luo Z, Guo C, Tang F, Xu X, Wang X, Wang M, Chen J, Abliz Z. In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging. Sci Rep. 2015; 5: 14089. https://doi.org/10.1038/srep14089
14. Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, Goodman G, Feng Z, Gandara D, Fiehn O, Taguchi A. Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol. 2015; 33: 3880-6. https://doi.org/10.1200/ JCO.2015.61.7779
15. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015; 24: 1716-23. https://doi. org/10.1158/1055-9965.EPI-15-0427
16. Chen Y, Ma Z, Min L, Li H, Wang B, Zhong J, Dai L. Biomarker identification and pathway analysis by serum metabolomics of lung cancer. Biomed Res Int. 2015; 2015: 183624. https://doi.org/10.1155/2015/183624
17. Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O. Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites. 2015; 5: 192-210. https://doi.org/10.3390/ metabo5020192
18. Musharraf SG, Mazhar S, Choudhary MI, Rizi N, Attaur-Rahman. Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry. Sci Rep. 2015; 5: 8607. https://doi.org/10.1038/srep08607
19. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom W, Pass H, Kim K, Nguyen UT, Taylor SL, Kelly K, Fiehn O, Miyamoto S. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015; 8: 410-8. https://doi.org/10.1158/1940-6207.CAPR-14-0329
20. Wen CP, Zhang F, Liang D, Wen C, Gu J, Skinner H, Chow WH, Ye Y, Pu X, Hildebrandt MA, Huang M, Chen CH, Hsiung CA, et al. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res. 2015; 21: 193-200. https://doi. org/10.1158/1078-0432.CCR-14-0748
21. Calderón-Santiago M, Priego-Capote F, Turck N, Robin X, Jurado-Gámez B, Sanchez JC, Luque de Castro MD. Human sweat metabolomics for lung cancer screening. Anal Bioanal Chem. 2015; 407: 5381-92. https://doi.org/10.1007/ s00216-015-8700-8
22. An YJ, Cho HR, Kim TM, Keam B, Kim JW, Wen H, Park CK, Lee SH, Im SA, Kim JE, Choi SH, Park S. An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. Int J cancer. 2015; 136: 162-71. https://doi.org/10.1002/ ijc.28949
23. Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, Stanimirova I, Daszykowski M, Korzeniewska A, Jankowska R, Mlynarz P. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014; 100: 369-80. http://dx.doi.org/10.1016/j. jpba.2014.08.020
24. Li Y, Song X, Zhao X, Zou L, Xu G. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 966: 147-53. https://doi.org/10.1016/j. jchromb.2014.04
25. Wu Q, Wang Y, Gu X, Zhou J, Zhang H, Lv W, Chen Z, Yan C. Urinary metabolomic study of non-small cell lung carcinoma based on ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Sep Sci. 2014; 37: 1728-35. https:// doi.org/10.1002/jssc.201400222
26. Mathé EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, Shields PG, Idle JR, Smith PB, Anami K, Kazandjian DG, Hatzakis E, Gonzalez FJ, Harris CC. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014; 74: 3259-70. https://doi.org/10.1158/0008-5472. CAN-14-0109
27. Wen T, Gao L, Wen Z, Wu C, Tan CS, Toh WZ, Ong CN. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol Biosyst. 2013; 9: 2370-8. https://doi.org/10.1039/c3mb70138g
28. Chen Y, Ma Z, Li A, Li H, Wang B, Zhong J, Min L, Dai L. Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/ mass spectrometry. J Cancer Res Clin Oncol. 2015; 141: 705-18. https://doi.org/10.1007/s00432-014-1846-5
29. Wedge DC, Allwood JW, Dunn W, Vaughan AA, Simpson K, Brown M, Priest L, Blackhall FH, Whetton AD, Dive C, Goodacre R. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal Chem. 2011; 83: 6689-97. https://doi.org/10.1021/ ac2012224
30. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, Yamakado M, Imamura F, Kodama K. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer. 2010; 10: 690. https://doi.org/10.1186/1471-2407-10-690
31. Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 2011; 10: 221-30. https://doi.org/10.1021/pr100899x
32. An Z, Chen Y, Zhang R, Song Y, Sun J, He J, Bai J, Dong L, Zhan Q, Abliz Z. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res. 2010; 9: 4071-81. https://doi.org/10.1021/pr100265g
33. Yang Q, Shi X, Wang Y, Wang W, He H, Lu X, Xu G. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J Sep Sci. 2010; 33: 1495-503. https://doi. org/10.1002/jssc.200900798
34. Klupczynska A, Derezinski P, Garrett TJ, Rubio VY, Dyszkiewicz W, Kasprzyk M, Kokot ZJ. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics. J Cancer Res Clin Oncol. 2017; 143: 649-59. https://doi.org/10.1007/s00432-017-2347-0
35. Louis E, Cantrelle FX, Mesotten L, Reekmans G, Bervoets L, Vanhove K, Thomeer M, Lippens G, Adriaensens P. Metabolic phenotyping of human plasma by 1H-NMR at high and medium magnetic field strengths: a case study for lung cancer. Magn Reson Chem. 2017; 55: 706-13. https:// doi.org/10.1002/mrc.4577
36. Ros-Mazurczyk M, Wojakowska A, Marczak L, Polanski K, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening-a pilot study. Acta Biochim Pol. 2017. https://doi.org/10.18388/abp.2017_1517
37. Duarte IF, Rocha CM, Gil AM. Metabolic profiling of biofluids: potential in lung cancer screening and diagnosis. Expert Rev Mol Diagn. 2013; 13: 737-48. https://doi.org/1 0.1586/14737159.2013.83557038
38. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011; 208: 313-26. https://doi.org/10.1084/jem.2010147039
39. Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014; 14: 263-76. https://doi.org/10.1038/nrc3701
40. Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010; 33: 469-77. https://doi. org/10.1007/s10545-010-9061-2
41. Awwad HM, Geisel J, Obeid R. The role of choline in prostate cancer. Clin Biochem. 2012; 45: 1548-53. https:// doi.org/10.1016/j.clinbiochem.2012.08.012
42. Gillies RJ, Gatenby RA. Metabolism and its sequelae in cancer evolution and therapy. Cancer J. 2015; 21: 88-96. https://doi.org/10.1097/PPO.032454R1032454R10102
43. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 2013; 230: 350-5. https://doi.org/10.1002/path.4218
44. He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol. 2017; 43: 81-95. https://doi.org/10.108 0/1040841X.2016.1176988
45. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet. 2003; 33: 228-37. https://doi.org/10.1038/ng1090
46. Maher B. Personal genomes: the case of the missing heritability. Nature. 2008; 456: 18-21. https://doi. org/10.1038/456018a
47. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74. https://doi. org/10.1016/j.cell.2011.02.013
48. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009; 8: 41. https://doi.org/10.1186/1476-4598-8-41
49. Sellers K, Fox MP, Bousamra M, Slone SP, Higashi RM, Miller DM, Wang Y, Yan J, Yuneva MO, Deshpande R, Lane AN, Fan TW. Pyruvate carboxylase is critical for nonsmall-cell lung cancer proliferation. J Clin Invest. 2015; 125: 687-98. https://doi.org/10.1172/JCI72873DS1
50. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, Carreira IM, Melo JB, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte IF. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010; 9: 319-32. https://doi.org/10.1021/pr9006574
51. Chen W, Zu Y, Huang Q, Chen F, Wang G, Lan W, Bai C, Lu S, Yue Y, Deng F. Study on metabonomic characteristics of human lung cancer using high resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. Magn Reson Med. 2011; 66: 1531-40. https://doi. org/10.1002/mrm.22957
52. Rezola A, Pey J, Rubio á, Planes FJ. In-silico prediction of key metabolic differences between two non-small cell lung cancer subtypes. PLoS One. 2014; 9: e103998. https://doi. org/10.1371/journal.pone.0103998
53. Caiola E, Brunelli L, Marabese M, Broggini M, Lupi M, Pastorelli R. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget. 2016; 7: 51462-72. https://doi. org/10.18632/oncotarget.9849
54. Sacco J, Al-Akhrass H, Wilson CM. Challenges and strategies in precision medicine for non-small cell lung cancer. Curr Pharm Des. 2016; 22: 4374-85. https://doi.org /10.2174/1381612822666160603014932
55. Guo L, Milburn MV, Ryals JA, Lonergan SC, Mitchell MW, Wulff JE, Alexander DC, Evans AM, Bridgewater B, Miller L, Gonzalez-Garay ML, Caskey CT. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci U S A. 2015; 112: E4901-10. https://doi.org/10.1073/pnas.1508425112
56. Robles AI, Harris CC. Integration of multiple 'OMIC' biomarkers: a precision medicine strategy for lung cancer. Lung Cancer. 2016; 107: 50-8. https://doi.org/10.1016/j. lungcan.2016.06.003
57. Teng ZY, Cheng XL, Cai XT, Yang Y, Sun XY, Xu JD, Lu WG, Chen J, Hu CP, Zhou Q, Wang XN, Li SL, Cao P. Ancient Chinese formula Qiong-Yu-Gao protects against cisplatin-induced nephrotoxicity without reducing antitumor activity. Sci Rep. 2015; 5: 15592. https://doi. org/10.1038/srep15592
58. Bathen TF, Geurts B, Sitter B, Fjøsne HE, Lundgren S, Buydens LM, Gribbestad IS, Postma G, Giskeødegård GF. Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery. PLoS One. 2013; 8: e61578. https://doi.org/10.1371/journal. pone.0061578
59. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: a golden opportunity to transform outcomes in earlystage non-small cell lung cancer. Clin Cancer Res. 2015; 21: 5439-44. https://doi.org/10.1158/1078-0432.CCR-15-0354